thiophenes has been researched along with thromboplastin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dann, O; Geratz, JD; Loewe, H; Tidwell, RR; Volz, G; Zeh, D | 1 |
| Goto, K; Imamura, H; Nakanishi, M | 1 |
| Dressel, D; Grube, M; Kroemer, HK; Kunert-Keil, C; Ritter, CA; Sperker, B | 1 |
| Perzborn, E; Pohlmann, J; Roehrig, S; Schlemmer, KH; Strassburger, J; Straub, A; Wilmen, A | 1 |
| Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E | 1 |
| Depasse, F; Elalamy, I; Gerotziafas, GT; Perzborn, E; Samama, MM | 1 |
| Becka, M; Breddin, HK; Graff, J; Harder, S; Kubitza, D; Misselwitz, F; von Hentig, N | 1 |
| Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Jakubowski, JA; Li, Y; Linden, MD; Michelson, AD; Sugidachi, A; Tarnow, I; Winters, KJ | 1 |
| Castellino, FJ; Fernández, JA; Furlan-Freguia, C; Griffin, JH; Mosnier, LO; Niessen, F; Rosen, H; Ruf, W; Weiler, H | 1 |
| Bareiss, P; Kessler, L; Morel, O; Ohlmann, P | 1 |
| Jiang, X; Wong, PC | 1 |
| Chantarangkul, V; Guinet, C; Samama, MM; Tripodi, A | 1 |
| Giese, C; Harenberg, J; Krämer, R; Marx, S; Weiss, C | 1 |
| Haynes, LM; Mann, KG; Orfeo, T | 1 |
| Burggraaf, J; Kluft, C; Kret, R; Meijer, P | 1 |
| Chidiac, J; Jamshedov, J; Klein, C; Mirshahi, M; Mirshahi, P; Mirshahi, S; Perzborn, E; Soria, C; Soria, J; Varin, R | 1 |
| Brinkman, HJ; de Laat, B; Dinkelaar, J; Leyte, A; Molenaar, PJ; Ninivaggi, M | 1 |
| Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA | 1 |
| Arachchillage, DR; Cohen, H; Efthymiou, M; Lawrie, AS; Machin, SJ; Mackie, IJ | 1 |
| Buetehorn, U; Heitmeier, S; Laux, V; Perzborn, E | 1 |
1 review(s) available for thiophenes and thromboplastin
| Article | Year |
|---|---|
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine | 2010 |
1 trial(s) available for thiophenes and thromboplastin
| Article | Year |
|---|---|
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Topics: Administration, Oral; Adult; Anticoagulants; Blood Coagulation; Blood Platelets; Cross-Over Studies; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time; Thromboplastin; Time Factors | 2007 |
18 other study(ies) available for thiophenes and thromboplastin
| Article | Year |
|---|---|
Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases.
Topics: Amidines; Anticoagulants; Benzimidazoles; Benzofurans; Blood Coagulation Tests; Humans; Indoles; Kallikreins; Protease Inhibitors; Structure-Activity Relationship; Thiophenes; Thrombin; Thromboplastin; Time Factors; Trypsin Inhibitors | 1978 |
[Studies on anti-inflammatory agents. 18. Effect of 2-amino-3-ethoxycarbonyl-6-benzyl-4,5,6,7-tetrahydrothieno(2,3-c)pyridine (Y-3642) on the release of histamine in vitro and in vivo].
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Benzyl Compounds; Depression, Chemical; Dextrans; Diphenhydramine; Flufenamic Acid; Histamine Release; In Vitro Techniques; Mast Cells; Phenylbutazone; Polymyxins; Pyridines; Rats; Thiophenes; Thromboplastin | 1971 |
Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.
Topics: Blotting, Western; Busulfan; Cell Cycle; Cell Division; Cell Line; DNA, Complementary; Dose-Response Relationship, Drug; G2 Phase; Glutathione Transferase; Humans; Isoenzymes; Plasmids; Thiophenes; Thromboplastin; Time Factors; Transfection | 2002 |
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Topics: Animals; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Inhibitory Concentration 50; Morpholines; Rabbits; Rats; Rivaroxaban; Serine Proteinase Inhibitors; Species Specificity; Thiophenes; Thromboplastin; Venous Thrombosis | 2005 |
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Jugular Veins; Ligation; Morpholines; Nadroparin; Polysaccharides; Rabbits; Random Allocation; Rivaroxaban; Thiophenes; Thromboplastin; Venous Thrombosis | 2007 |
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
Topics: Administration, Oral; Antithrombin III; Blood Platelets; Factor Xa Inhibitors; Humans; In Vitro Techniques; Inhibitory Concentration 50; Kinetics; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time; Thromboplastin; Time Factors | 2007 |
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Topics: Adenosine Diphosphate; Annexin A5; Biotransformation; Blood Coagulation Factors; Blood Platelets; Clot Retraction; Collagen; Humans; Monocytes; Phosphatidylserines; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Thrombin; Thromboplastin | 2008 |
Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality.
Topics: Animals; beta-Alanine; Capillary Leak Syndrome; Capillary Permeability; Disseminated Intravascular Coagulation; Endothelial Protein C Receptor; Endothelium, Vascular; Endotoxins; Enzyme Activation; Glycoproteins; Hirudins; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins; Protein C; Receptor, PAR-1; Receptors, Cell Surface; Receptors, Lysosphingolipid; Signal Transduction; Specific Pathogen-Free Organisms; Sphingosine-1-Phosphate Receptors; Systemic Inflammatory Response Syndrome; Thiophenes; Thrombin; Thromboplastin | 2009 |
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors | 2010 |
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.
Topics: Blood Coagulation; Calibration; Drug Monitoring; Factor Xa Inhibitors; Feasibility Studies; Fibrinolytic Agents; Humans; Morpholines; Prothrombin Time; Reference Standards; Rivaroxaban; Tetrazolium Salts; Thiophenes; Thromboplastin | 2011 |
Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
Topics: Anticoagulants; Blood Coagulation; Calibration; Coagulants; Humans; Indicators and Reagents; International Normalized Ratio; Morpholines; Plasma; Prothrombin Time; Recombinant Proteins; Regression Analysis; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thromboplastin | 2011 |
Rivaroxaban delivery and reversal at a venous flow rate.
Topics: Administration, Oral; Anticoagulants; Blood Flow Velocity; Dose-Response Relationship, Drug; Factor V; Factor Va; Factor Xa; Humans; Models, Biological; Morpholines; Regional Blood Flow; Risk Factors; Rivaroxaban; Thiophenes; Thromboplastin; Venous Thrombosis | 2012 |
Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.
Topics: Anticoagulants; Biological Assay; Blood Coagulation; Factor Xa Inhibitors; Fondaparinux; Humans; Kinetics; Morpholines; Partial Thromboplastin Time; Polysaccharides; Rivaroxaban; Thiophenes; Thromboplastin; Time Factors | 2013 |
Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Topics: Anticoagulants; Blood; Blood Coagulation; Blood Platelets; Erythrocytes; Factor XIII; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Humans; Morpholines; Permeability; Plasma; Risk Factors; Rivaroxaban; Thiophenes; Thrombin; Thrombolytic Therapy; Thromboplastin; Thrombosis; Time Factors | 2013 |
In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
Topics: Anticoagulants; Area Under Curve; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Calibration; Fibrinolytic Agents; Humans; Morpholines; Plasma; Prothrombin; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Time Factors; Vitamin K | 2013 |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Blood Platelets; Dabigatran; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Fibrin; Humans; Lab-On-A-Chip Devices; Male; Microscopy, Confocal; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Thrombosis | 2014 |
Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Drug Monitoring; Female; Humans; Male; Middle Aged; Morpholines; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes; Thromboplastin | 2014 |
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Topics: Animals; Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Blood Platelets; Enzyme-Linked Immunosorbent Assay; Factor Xa Inhibitors; Humans; Male; Morpholines; Plasma; Platelet Count; Protein C; Prothrombin; Rats; Rats, Wistar; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin; Thrombomodulin; Thrombophilia; Thromboplastin | 2014 |